Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are primarily diagnosed with PTSD (Posttraumatic Stress Disorder: 309.81) using DSM-IV-TR criteria. The CAPS-DX (Clinician-Administered PTSD Scale-DX) and M.I.N.I. (The Mini International Neuropsychiatric Interview, Japanese version 5.0.0. \[2003\]) will be used for diagnosis~* Pathologic condition: Patients who experienced a motor vehicle accident (MVA) with severe or potential severe physical injury more than 3 months ago but less than 12 months ago~* Patients aged 20 and \<65 at the time of signing the Informed consent~* Male and female patients~* Inpatient/outpatient status: Both are permitted~* Patients who are able to give written informed consent in person (i.e., patients who are capable of giving written informed consent on their own)~* Patients whose combined score of the CAPS-SX standard B, C, and D is over 50~Exclusion Criteria:~* Patients primarily diagnosed with a DSM-IV-TR Axis I disorder other than PTSD (e.g. major depressive disorder, dysthymic disorder, specific phobia \[simple phobia\], obsessive-compulsive disorder, panic disorder, etc.) within 6 months of week -4 (start of baseline phase)~* Patients presenting with a current major depressive episode that preceded the diagnosis of PTSD~* Patients receiving disability payments due to PTSD or other psychiatric diseases~* Patients currently engaged in compensation litigation whereby personal gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders~* Patients who meet the DSM-IV-TR criteria for substance abuse or dependence (alcohol or drugs) within 6 months of Week -4 (start of baseline phase)~* Patients with history of a suicide attempt within 6 months before Week -4 (start of baseline phase), or have, in the opinion of the investigator, C. high risk of suicide according to the MINI at Week -4~* Patients who are pregnant, lactating or of childbearing potential and are likely to become pregnant~* Patients receiving electro-convulsive therapy (ECT) prior to Week -4 (start of baseline phase)~* Patients receiving another investigational product within 12 weeks before Week -4 (start of baseline phase)~* Patients with a history or complication of manic psychosis~* Patients with a history or complication of convulsive disorder (epilepsy, etc.)~* Patients with a diagnosis or complication of a cognitive disorder (MMSE \<=24 points)~* Patients with a history and complication of serious cerebral organic disorder. (e.g. cerebrovascular disorder, meningitis, degenerative disease and other neurological disorders and seizures; however, bleeding in the upper arachnoid membrane should not be excluded)~* Patients unable or unwilling to undergo the fMRI procedure (e.g., cerebrovascular clipping surgery, pacemaker, any internal metals with magnetism, and claustrophobia)~* Patients with glaucoma~* Patients with a known tendency for bleeding or those with predisposing conditions~* Patients with a history of hypersensitivity to paroxetine~* Patients with serious physical symptoms (cardiac, hepatic and renal dysfunction, or hematopoietic dysfunction, etc.). For seriousness, Grade 3 of Criteria for seriousness of adverse reactions to drugs, etc. (Yakuan No.80) is used as an index~* Patients with a history or complication of cancer or malignant tumour~* Patients with chronic hepatitis type B and/or C which is positive of hepatitis B surface antigen (HBsAg) and/or hepatitis C antibody~* Others whom the investigator or sub-investigator considers ineligible for or unable to participate in the investigation~* Criteria at Week 0 (start of Treatment Phase):~Subjects whose drug compliance rate for Drug 1 (Run-in Phase placebo) is \<80% between Week -4 and Week 0;~Subjects whose CAPS-SX total score of the standard B, C, and D at Week 0 varied by 25% or more compared with those at Week -2

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- paroxetine (Type: EXPERIMENTAL): Drug 2 (20 mg/day or placebo) will be administered once daily after supper for the first two weeks after the run-in phase. If the investigator/subinvestigator judges that a sufficient response is achieved, Drug 2 will be continued for the remaining period. If a sufficient response is not achieved with Drug 2 but treatment is well tolerated, the dose will be titrated to one step higher level until a sufficient response is achieved \[i.e., Drug 3 (30 mg/day or placebo) → Drug 4 (40 mg/day or placebo) → Drug 5 (50 m/day or placebo)\] at intervals of at least two weeks by once daily administration after supper. Once a sufficient response is achieved, that dose will be continued.
- placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).